472 related articles for article (PubMed ID: 24532544)
1. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
2. Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke: the CAPAMIS Study, 3-year follow-up.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; de Diego-Cabanes C; Satue-Gracia E; Vila-Rovira A; Torrente Fraga C;
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1577-84. PubMed ID: 24656243
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: The CAPAMIS study, three-year follow-up.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; de Diego-Cabanes C; Hospital-Guardiola I; Jariod-Pamies M;
Vaccine; 2014 Jan; 32(2):252-7. PubMed ID: 24262314
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A; Gomez F; Raga X; de Diego C; Satue E; Salsench E;
BMC Public Health; 2012 Mar; 12():222. PubMed ID: 22436146
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
9. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
10. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.
Wiemken TL; Carrico RM; Klein SL; Jonsson CB; Peyrani P; Kelley RR; Aliberti S; Blasi F; Fernandez-Gonzalez R; Lopardo G; Ramirez JA;
Vaccine; 2014 Apr; 32(19):2198-203. PubMed ID: 24613522
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
[TBL] [Abstract][Full Text] [Related]
14. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
16. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.
Principi N; Esposito S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28029140
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.
Ochoa-Gondar O; Vila-Corcoles A; Ansa X; Rodriguez-Blanco T; Salsench E; de Diego C; Raga X; Gomez F; Valdivieso E; Fuentes C; Palacios L;
Vaccine; 2008 Apr; 26(16):1955-62. PubMed ID: 18343541
[TBL] [Abstract][Full Text] [Related]
19. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.
Johnstone J; Marrie TJ; Eurich DT; Majumdar SR
Arch Intern Med; 2007 Oct; 167(18):1938-43. PubMed ID: 17923592
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
